GLP1R and type 2 diabetes mellitus: Survodutide, a dual agonist of the Gcg and GLP-1 receptors, has demonstrateddose-dependent reductions in both HbA1c and body weight over a 16-weektreatment period in patients with T2D, compared to placebo.